Targets › ABCC4
1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Dec 2026.
ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes physiological compounds and xenobiotics from cells. Transports a range of endogenous molecules that have a key role in cellular communication and signaling, including cyclic nucleotides such as cyclic AMP (cAMP) and cyclic GMP (cGMP), bile acids, steroid conjugates, urate, and prostaglandins. (UniProt, O15439)
Open in Phaseline: the race on ABCC4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Harvard School of Public Health (HSPH) | DTG/ABC/3TC Integrase strand transfer inhibitor (dolutegravir) combined with nucleoside reverse transc | INTEGRASE, ABCC4, POLR2A | Phase 4 | HIV | Dec 2026 |
HIV (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.